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doi:10.1016/j.jtcvs.2008.04.019Objective: Risk factors for poor outcome with congenital complete heart block in-
clude prematurity, low birth weight, hydrops, low ventricular rates, and congenital
heart disease. In this group, medical therapy is often ineffective, pacing is technically
challenging, and mortality exceeds 80%. The purpose of this study is to assess out-
comes of patients with congenital complete heart block who were paced in the first
24 hours after birth owing to the presence of known risk factors.
Methods: We performed a retrospective review of patients with congenital complete
heart block paced in the first 24 hours after birth at our institution between November
1, 1995, and July 31, 2007.
Results: Thirteen patients were identified, 4 of whom had heterotaxy syndrome.
Eleven patients had temporary epicardial pacing wires placed; 2 received permanent
pacemakers as the initial mode of pacing. There were 7 deaths (54% mortality) at
a mean age of 19.9 6 19 days. Among 7 patients with structural heart disease, there
was 1 survivor. Among 6 patients with structurally normal hearts, there were 5 survi-
vors (P5 .025). Patients with temporary wires who survived to permanent pacemaker
implantation (6/11) used their temporary leads for 33.8 6 18.3 days.
Conclusions: In the severely affected fetus with congenital complete heart block and
significant structural heart disease, outcomes remain poor; however, neonates with
congenital complete heart block and structurally normal hearts who are monitored an-
tenatally and delivered in a planned fashion at an institution capable of early pacing
can have favorable outcomes. The use of temporary pacing wires is an option in
the management of these patients.
C
ongenital complete heart block (CCHB) is estimated to occur in 1 of every
15,000 to 22,000 live births,1,2 with 25% to 33% of cases associated with con-
genital heart disease.3 Historically, CCHB was thought to be a relatively be-
nign condition, with the only significant morbidity being the need for pacemaker
implantation to guard against the risk of Stokes-Adams attacks and sudden cardiac
death.1,4,5 These diagnoses were typically made many months or even years after
birth, when outcome is generally favorable.6 Clinical presentation of CCHB in utero
or in the neonatal period represents a more lethal condition, with overall mortality in
those with structurally normal hearts estimated at 19% to 31%.7,8 In the presence of
associated congenital heart disease, outcome is even worse.9 Identified risk factors for
poor outcomes in prenatally diagnosed CCHB include the presence of hydrops,10,11
low ventricular rate (usually defined as,55 beats/min),9,12,13 and prematurity,7 mak-
ing this a different clinical entity from the historical descriptions. In affected newborns
with the aforementioned risk factors, mortality may exceed 80%,13,14 prompting some
authors to argue for a new definition of CCHB based on early age at diagnosis.15
The purpose of this study was to report the experience at our institution with pacing
in the first 24 hours after birth for high-risk infants born with CCHB, including the useThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 767
Surgery for Congenital Heart Disease Glatz et al
CH
DAbbreviations and Acronyms
CCHB 5 congenital complete heart block
of temporary epicardial pacing wires as a staged approach to
permanent pacing. Pacing in the first 24 hours after birth is
performed at our institution for CCHB in the setting of
compromised cardiac output or if there are indications for im-
pending circulatory collapse. Prenatally, these signs include
hydrops, ventricular dysfunction, very low fetal heart rates
(,45 beats/min), or fetal echocardiographic evidence of
impending ventricular decompensation. Postnatally, ongoing
metabolic acidosis despite optimal medical management
prompts early pacing. Thus, inclusion of only those patients
paced during this time window ensures that our study popu-




Study patients were identified from our institutional surgical data-
base. Entry criteria were the diagnosis code of congenital heart block
or third-degree atrioventricular block with either permanent or tem-
porary pacemaker implantation in the first 24 hours after birth
between November 1, 1995, and July 31, 2007. Patients were
excluded if heart block occurred as a result of a separate surgical
procedure. Our electrocardiographic database was queried to ascer-
tain the total number of patients with a diagnosis of CCHB in the
immediate newborn period.
Study Protocol
The medical records of the identified patients were retrospectively
reviewed. Data reviewed included prenatal records, inpatient re-
cords including the specifics of the delivery, and outpatient records.
A database was created to include the following patient characteris-
tics: gender, gestational age at diagnosis, fetal echocardiographic
findings (structural anatomy, heart rate, ventricular function, associ-
ated hydrops), fetal treatment, fetal course, maternal antibody status
(if known), gestational age at delivery, birth weight, heart rate at
birth, clinical course at birth, first postnatal echocardiogram, indica-
tion for pacing in the first 24 hours, type of pacemaker implanted,
and clinical course after pacemaker implantation (duration of use
of temporary leads, pacemaker complications/side effects).
Surgical and Pacemaker Considerations
In our study group, 2 patients had permanent pacing systems as the
initial pacing modality. In both cases, the pacemaker was a Med-
tronic Thera SR 8960i with a single epicardial ventricular lead set
in the VVI mode (Medtronic, Inc, Minneapolis, Minn). The pace-
maker was placed in a subrectus pocket in an abdominal location.
The remaining 11 patients had surgical placement of temporary
epicardial leads. Three to 4 temporary pacing wires were affixed
to the ventricular epicardial surface via either a small subxiphoid
or anterior chest incision. A median sternotomy approach was
used if additional temporary atrial pacing wires were implanted.768 The Journal of Thoracic and Cardiovascular Surgery c SepThe wires were then brought to the skin surface and sutured in place.
In all cases, 1 to 2 skin leads were also sutured in place. Epicardial
wires were tested to ensure adequate pacing thresholds.
Planned Early Pacing
In 8 of our patients, pacing was performed in a planned fashion.
These patients were all monitored closely through the Fetal Heart
Program at The Children’s Hospital of Philadelphia. On the basis
of prenatal findings that placed them in a high-risk subset, these
infants were delivered via scheduled cesarean section and then ven-
tricular pacing was initiated via temporary epicardial wires immedi-
ately after birth. To implement this, a pediatric cardiovascular team
consisting of a pediatric cardiothoracic surgeon, cardiac anesthesiol-
ogist, electrophysiologist, echocardiographer, and cardiac surgery
nurses were present at the time of delivery of the infant for prompt
evaluation, resuscitation, and treatment, which included placement
of umbilical lines, anesthetizing the patient, and intubation followed
by placement of the temporary leads as described earlier.
Statistical Considerations
Summary data were reported as frequencies, medians with ranges,
and means with standard deviations where appropriate. Differences
between groups (survivors vs nonsurvivors) were evaluated by
either t test for quantitative variables or log rank for dichotomous
variables. Survival rates were assessed by Kaplan–Meier curves.
The Institutional Review Board of The Children’s Hospital of
Philadelphia approved this retrospective study and granted a waiver
of informed consent.
Results
Between November 1, 1995, and July 31, 2007, a total of 24
patients were identified with the diagnosis of CCHB at birth
or earlier. Of these 24 patients, 13 (54%) received pacing in
the first 24 hours after birth. Indications for pacing in these 13
patients included hydrops (6/13, 46%), profound fetal brady-
cardia (,45 beats/min) (3/13, 23%), severe intrauterine
growth retardation (1/13, 8%), and refractory low cardiac
output after birth (3/13, 23%).
Clinical characteristics of our patient population are
summarized in Table 1. There were 4 boys and 9 girls. In 2
patients the diagnosis of CCHB was made at the time of
birth; in the remaining 11 patients the diagnosis was made
prenatally at gestational ages ranging from 18 to 30 weeks
(mean 33 6 3.8 weeks). Birth weights ranged from 990 to
4000 g (mean 1953 6 903 g). Seven (54%) patients had
significant structural heart disease, including heterotaxy
with atrioventricular canal (3/7, 43%), heterotaxy with total
anomalous pulmonary venous connection (1/7, 14%), dou-
ble-outlet right ventricle (1/7, 14%), hemodynamically sig-
nificant patent ductus arteriosus with sinus venosus type
atrial septal defect (1/7, 14%), and multiple ventricular septal
defects with a spongiform myocardium (1/7, 14%). Of the 7
patients with structural heart disease, 3 (43%) represented
a form of single-ventricle physiology. Two of 13 (15%)
patients had permanent pacemakers placed at birth, and the
remaining 11 had temporary pacing wires used as their initialtember 2008


















w/TemP Outcome Cause of death




2 F Prenatal 34 2630 Perm Hydrops VVI Heterotaxy, TAPVC NA Death Hypotension,
anasarca,
support withdrawn
3 F Birth 29 990 Temp HR , 45 VVI Heterotaxy,
transitional AVC




4 F 19 30 1859 *Temp Hydrops VVI Heterotaxy,
unbalanced AVC
42 Death Anasarca, SIRS,
sepsis, MOSF,
support withdrawn
5 F 30 37 4000 Temp Hydrops DDD DORV 0 Death ventricular fibrillation
arrest
6 M Birth 26 1282 Temp Low cardiac
output
DDD Normal 1 Death Hypotension, Grade IV
ICH, support
withdrawn




20 Death MOSF, support
withdrawn
8 F 30 38 2900 *Temp HR , 45 VVI Normal 18 Alive
9 F 22 31 1200 *Temp Hydrops VVI VSDs, spongy
myocardium
67 OHT, alive
10 M 22 34 1180 *Temp IUGR,
HR ,45
VVI Normal 36 Alive
11 F 18 33 1500 *Temp Hydrops VVI Normal 34 Alive
12 F 2nd trim 34 1700 *Temp HR , 45 VVI Normal 16 Alive
13 F 23 32 1900 *Temp HR , 45 VVO Normal 32 Alive
GA, Gestational age; PM, pacemaker; TemP, Temporary pacing leads; PDA, patent ductus arteriosus; SVASD, sinus venosus atrial septal defect; TAPVC, total
anomalous pulmonary venous connection; AVC, atrioventricular canal; SIRS, systemic inflammatory response syndrome; MOSF, multiorgan system failure;
DORV, double-outlet right ventricle; HR, heart rate; IUGR, intrauterine growth retardation; ICH, intracranial hemorrhage; VSD, ventricular septal defect,
OHT, orthotopic heart transplant; NA, not applicable. *Temporary wires placed in a planned manner immediately after scheduled delivery.CH
Dmodality of pacing. Two of 11 patients with temporary
pacing wires also had additional atrial epicardial wires
implanted.
Early pacing was planned in 8 patients and was initiated
soon after birth. In 4 patients, delivery of the infant via cesar-
ean section was performed at The Children’s Hospital of
Philadelphia and the infant was immediately taken to an ad-
jacent operating room for implantation of temporary pacing
wires. In another 2 patients, the pediatric cardiovascular
team set up an operating station in the delivery room of the
affiliated adult hospital and temporary pacing was initiated
soon after birth. In the remaining 2 patients, the infants
were transported immediately after birth at the affiliated adult
hospital to The Children’s Hospital of Philadelphia cardiac
surgical suite for temporary pacing.
The 5 patients who did not receive pacing wires immedi-
ately after birth all had a trial of medical therapy in the cardiac
intensive care unit. This included mechanical ventilation,
inotropic support, optimization of acid/base status, and anThe Journal of Thoisoproterenol (Isuprel) infusion for rate support. Because of
ongoing difficulties supporting adequate cardiac output,
these patients had pacing wires placed within the first 24
hours after birth.
At the time of initial pacemaker implantation, there were
no other surgical procedures performed, with the exception
of ligation of a patent ductus arteriosus in 1 patient. There
were 7 deaths at an average age of 19.9 6 19 days for an
overall mortality rate of 54%. There were no intraoperative
deaths. Causes of death included ventricular fibrillation arrest
(n 5 1), pulmonary hypertensive crisis (n 5 1), and refrac-
tory heart failure (n 5 5) (see Table 1 for more details about
causes of death). Of the 7 patients with significant structural
heart disease, the sole survivor was a patient with multiple
ventricular septal defects and a spongy myocardium. This
patient ultimately underwent cardiac transplantation. Among
the subgroup with single-ventricle physiology, mortality was
100% (3/3 patients). Among the 6 patients with structurally
normal hearts, there was 1 death. A Kaplan–Meier survivalracic and Cardiovascular Surgery c Volume 136, Number 3 769
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Dcurve comparing patients with and without structural heart
disease is shown in Figure 1.
There was no statistically significant difference between
survivors and nonsurvivors in gestational age at birth or birth
weight (Table 2). All survivors eventually received perma-
nent pacemakers. Survivors used their temporary pacing
leads for as long as 67 days (mean 33.86 18.3 days). All sur-
vivors are doing well at maximum follow-up of 10.9 years
(mean 5.2 6 4.7 years).
Table 3 summarizes the possible predictors of outcome
assessed in our patient population. The presence of any form
of structural heart disease was a significant predictor of
mortality (P 5 .025), while heterotaxy syndrome (P 5 0.1)
and single-ventricle heart disease (P5 .059) showed a trend
toward worse outcome. Survival was significantly associated
with the use of maternal steroids during pregnancy (P 5
.004). A trend toward better outcome was seen in patients
whose diagnosiswasmade antenatally (P5 .087) and in those
in whom pacing was done in a planned manner immediately
after birth on the basis of prenatal factors (P 5 .065).
Discussion
Among patients with a prenatal diagnosis of CCHB, there
appear to be certain features that portend a particularly grave
outcome. These include prematurity, low birth weight, low
ventricular rate (,55 beats/min), significant structural heart
disease, evidence for ventricular dysfunction or associated
cardiomyopathy, and the presence of hydrops fetalis.7,9-13
In the presence of hydrops, reported mortality rates for in-
fants born with CCHB exceed 80%.13,14 In the most recent
series, CCHB associated with structural heart disease con-
Figure 1. Kaplan–Meier survival curve for patients with congeni-
tal complete heart block paced in the first 24 hours after birth both
with (n5 7) andwithout (n5 6) structural heart disease (P5 .025).770 The Journal of Thoracic and Cardiovascular Surgery c Septinues to have high mortality, whereas outcomes of prenatally
diagnosed isolated CCHB seem to be much improved in the
current era of aggressive prenatal and postnatal manage-
ment.16 However, hydrops and cardiac enlargement remain
risk factors for poor outcome.17
Antenatal treatment of CCHB has included (1) beta-
sympathomimetics to increase the fetal heart rate;11,18-20 (2)
plasmapheresis21 and steroids11,22,23 to target the antibody-
mediated and inflammatory component; and (3) digoxin12
and/or lasix24 to treat associated ventricular dysfunction
and hydrops. Success with these therapies is largely anec-
dotal with no controlled clinical trials. There are also reports
of unsuccessful attempts at direct fetal pacing.25 In the se-
verely affected fetus, early delivery has been advocated.14
After birth, therapy typically includes aggressive medical
management coupled with pacing in those infants who do
not respond to medical therapies alone. There are significant
technical challenges to placement of a permanent pacemaker
in this group, inasmuch as these patients are often premature,
small, and clinically unstable, although there are anecdotal
reports of successful cases26-28 and a more recent report of
a larger series in which permanent pacemakers were used
in newborns with CCHB and a weight of at least 2.0 kg.29
In an attempt to circumvent these challenges, the successful
use of temporary pacing wires was reported in 2 cases by
Deloof and associates30 and 2 cases by Weindling and
colleagues.31 These cases support an argument for a staged
approach to pacing in high-risk infants using temporary
epicardial leads until the patient is large enough and stable
enough for permanent pacemaker implantation.
Because of the poor outcomes and limited therapeutic
options available, our institution has used the management
approach of early pacing for the high-risk neonate with
CCHB. As described in this study, this approach has evolved
to pacing identified high-risk neonates immediately after
birth. Planned early pacing of high-risk neonates with
CCHB potentially reduces the adverse consequences of pro-
found bradycardia and asystole soon after birth in the milieu
of increasing metabolic demands. Along with the initiation of
pacing soon after birth, central line placement and inotropic
drug infusions, if necessary, are also started immediately,
thus reducing the chances of hemodynamic lability during
transport to the intensive care unit. Our own experience
and that reported in the literature suggest a significant mortal-
ity in high-risk neonates with CCHB resulting from refrac-
tory low cardiac output. Once profound metabolic acidosis
occurs, effective myocardial stimulation despite high output
pacing may not be possible. All the neonates presented in this
study had either significant findings of low cardiac output in
utero or impending cardiovascular collapse soon after birth.
To date, this study represents the largest reported experi-
ence from a single institution with the use of pacing in the
first 24 hours after birth for the high-risk infant with
CCHB. In our experience, the survival for this high-risktember 2008
Glatz et al Surgery for Congenital Heart DiseaseTABLE 2. Comparison of quantitative variables between survivors and nonsurvivors of pacing in the first 24 hours after birth
for patients with congenital complete heart block
GA at birth (wk) Birth weight (g)
Duration of
temp leads (d) Duration of follow-up (d)
All patients 32.9 6 3.8 1953 6 903 752 6 1375
Nonsurvivors 32.3 6 4.7 2144 6 1095 19.9 6 19.2
Survivors 33.7 6 2.5 1730 6 638 33.8 6 18.3 1911 6 1715
P* NS NS
Data are presented as mean 6 standard deviation. *NS, Not significant; statistical significance is taken as P , .05.CH
Dsubgroup of infants with CCHB is 46% (6/13 patients). Al-
though our mortality figures are lower than those reported
in previous series, CCHB remains a potentially lethal condi-
tion. Overall, our population was fairly heterogeneous as
described. There were no statistically significant differences
between survivors and nonsurvivors on the basis of
gestational age at delivery or birth weight, suggesting that
these potential comorbidities do not play a significant role
in affecting survival outcome in this population group.
We also compared survivors and nonsurvivors on the ba-
sis of a number of other clinical characteristics that might
help predict which infants are at greater risk for poorer
outcomes. Improved survival was associated with the use
of maternal steroids, whereas the presence of structural heart
disease was associated with worse outcome. The association
between the use of steroids and improved outcome may be
confounded by the fact that steroids are typically not used
in cases of CCHB associated with structural heart disease,
where the etiology of the heart block is not likely to be im-
mune mediated. Nonetheless, there is recent evidence that
steroid use does improve outcome in cases of isolated
CCHB,32 so our practice is to treat the mothers of fetuses
with isolated CCHB or antibody-associated CCHB with
daily oral steroid (typically dexamethasone) from the time
of diagnosis. Stress-dose steroids are given intravenously
during labor, and then both mother and child are placed on
a slow steroid taper regimen after birth. In addition, steroids
are used in those pregnancies that require delivery of a prema-
ture infant to enhance fetal lung maturity, at the discretion of
our colleagues in maternal and fetal medicine.
There was a trend toward improved outcome among those
patients whose diagnosis was made antenatally and those
whose delivery was planned followed by immediate pacing.
Finally, there was a trend toward worse outcome in those pa-
tients with a form of heterotaxy syndrome or single-ventricle
heart disease.
Given the heterogeneity of our patient population, it is
instructive to examine trends among certain subgroups.
Among 7 patients with significant structural heart disease,
there is a sole survivor who was bridged to transplant with
temporary pacing wires. Among the 6 patients with structur-
ally normal hearts, there was only a single death—an infantThe Journal of Thoborn at 26 weeks of gestation at an outside hospital who
arrived at our institution profoundly acidotic. Thus, it appears
that CCHB paired with significant structural heart disease
approaches uniform mortality, whereas neonates with
CCHB and structurally normal hearts who are monitored
closely antenatally and delivered in a planned fashion at an
institution capable of early pacing can have favorable
outcomes.
Two of our patients received permanent pacemakers as
their initial pacing modality, the last in 1999. Both of these
patients died. Since then, it has been our consistent approach
to use temporary epicardial pacing wires in the high-risk ne-
onate with CCHB. When possible, we have followed these
severely affected fetuses through the Fetal Heart Program
at The Children’s Hospital of Philadelphia and planned
TABLE 3. Comparisons between groups of survivors and
nonsurvivors of pacing in the first 24 hours after birth for





(n 5 7) P*
Antenatal diagnosis 6 5 .087
Premature (,36 wk) 5 5 .429
LBW (,2 kg) 5 4 .367
Gender 5 female 4 female .14
Maternal steroids 6 1 .004
Maternal b-agonists 5 2 .132
Hydrops 2 4 .467
Birth at OSH 0 3 .131
CHD: 1-vent 0 3 .059
CHD: 2-vent 1 3 .367
CHD: heterotaxy 0 4 .109
CHD: any form 1 6 .025
Heart rate , 55 beats/min 6 7 NA
Planned TemP 6 2 .065
Numbers expressed are the incidence of the clinical characteristic occur-
ring in each subgroup. LBW, Low birth weight; OHS, outside hospital; CHD,
congenital heart disease; 1-vent, single ventricle; 2-vent, two ventricles;
TemP, temporary pacing leads; NA, not available. *Statistical significance
is taken as P , .05. Bold faced values are those that reached statistical
significance. Italic values are near significant (.05 and .1).racic and Cardiovascular Surgery c Volume 136, Number 3 771
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temporary epicardial wires for early pacing either in the de-
livery room or in an adjoining operating room. Eight patients
have been treated through this planned approach to fetal sur-
veillance, scheduled delivery, and immediate placement of
temporary pacing wires. Among these patients, the only
deaths occurred in 2 with significant structural heart disease.
All patients with structurally normal hearts who were man-
aged in this planned fashion survived to permanent pacing
and remain alive today, despite fetal factors that would place
them in a high-risk subset.
In total, 11 of our patients received temporary pacing leads
as the initial mode of pacing. This approach obviates the im-
mediate need to perform a larger-scale operation on a tenuous
neonate. Our practice is to use three or four epicardial wires
plus at least one skin wire to guard against increasing thresh-
olds that may occur in any individual wire. In 1 patient, the
leads had to be removed owing to infection at the site of
skin entry. By this point, the patient’s condition had stabi-
lized to the point that he could be further managed with an
isoproterenol infusion. In the other 10 patients, the leads
were all technical successes and provided effective electrical
pacing for up to 67 (33.8 6 18.3) days.
Two patients in our series had temporary atrial pacing
wires placed at the same time as the temporary ventricular
wires. In 1 of these patients, there was significant hypoten-
sion associated with DDD pacing and 1:1 atrioventricular
synchrony. When the post–ventricular atrial refractory period
was lengthened to effectively produce 2:1 atrioventricular
conduction, the blood pressure was significantly improved.
It is our hypothesis that a sudden drastic increase in heart
rate associated with DDD pacing and tracking of the atrial
rate is not well tolerated in these neonates. Instead, it is our
practice to initially pace in a VVI manner and slowly increase
the ventricular rate to physiologic levels.
There have been two recent reports28,29 in the literature on
the use of temporary pacing leads as a bridge to permanent
pacing in a small number of patients. Our study is the largest
to date that demonstrates that temporary pacing wires can be
a technically feasible method of pacing the high-risk neonate
with CCHB. All survivors in our patient population ulti-
mately received permanent pacemakers and all are doing
well at most recent follow-up (median duration of 2.2 years,
range 0.2–10.9 years). Permanent pacemakers were im-
planted when patients reached a point of clinical stability
and achieved a weight deemed suitable for a permanent pac-
ing system (typically .2 kg).
Our study is limited by its retrospective nature and small
sample size. We are only able to assess for associations be-
tween variables and outcomes and not causation. Also, ma-
ternal antibody status was not available in all patients with
isolated CCHB. Further, there have been changes in manage-
ment approaches that have occurred during the period of our
review that may impart bias. Finally, these results reflect the772 The Journal of Thoracic and Cardiovascular Surgery c Septexperience of a single institution and may not necessarily
generalize to other institutions.
In conclusion, the most severely affected infants with
CCHB continue to have a high risk of mortality despite max-
imal medical and surgical care. In our experience, the coex-
istence of significant structural heart disease portends
a particularly grave prognosis. However, in those with struc-
turally normal hearts, there is reason for optimism even in the
face of severe prematurity, low birth weight, in utero hy-
pdrops, or ventricular dysfunction. In these patients, the use
of temporary epicardial ventricular pacing wires implanted
by a minimally invasive approach can be used successfully
as a bridge to a permanent pacemaker.
Our recommended approach to the management of the fe-
tus with CCHB includes early diagnosis, close fetal surveil-
lance, and the use of maternal steroids in cases of isolated
CCHB followed by planned delivery at an institution with
the ability for early placement of temporary epicardial pacing
leads for the severely affected newborn.
Xuemei Zhang, a senior biostatistician in the Biostatistics and
Data Management Core of The Children’s Hospital of Philadelphia,
was instrumental in performing the statistical analysis for this study.
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